Both the RELAY and ACTIVE study reported that EGFR-TKIs with an antiangiogenic agent revealed consistent improved antitumor activity and favorable PFS in patients with TP53 and EGFR co-mutant NSCLC [13, 15, 16]. The gene discussed is TP53; the disease is non-small cell lung carcinoma.